Clinical Trial Update: A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers [Phase 2]

View source ↗

Summary

A Phase II trial evaluating nivolumab in patients with DNA damage repair gene alterations who progressed after standard treatment for metastatic solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dna Damage Repair Gene Alteration Related Cancers
• Solid Tumors

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Korean Cancer Study Group | Conditions: DDR Gene Mutation, Metastatic Solid Tumor | Phase 2 | Status: UNKNOWN